This Viewpoint discusses the emergence of prediction markets for clinical trials and drug approvals, identifies the risks of these markets, and proposes oversight methods to develop potential benefits.
No takes yet. Share an insight, caveat, or question.
Genevieve P. Kanter (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: